Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic silencing of tumor suppressor genes, like FBW7, contributes to human lung cancer development.
• DNA methyltransferase inhibitors, such as decitabine (DAC), can reverse epigenetic silencing.
• FBW7 acts as an E3 ligase targeting Mcl-1 for degradation, a pathway relevant to cancer cell survival.

Purpose of the Study:

• To investigate the effect of decitabine (DAC) on FBW7 expression and Mcl-1 levels in human lung cancer.
• To elucidate the mechanism by which DAC influences the FBW7/Mcl-1 signaling pathway.
• To evaluate the therapeutic potential of DAC, alone and in combination with venetoclax, for lung cancer treatment.

Main Methods:

• Treatment of human lung cancer cell lines and xenografts with decitabine (DAC).
• Analysis of FBW7 and Mcl-1 expression and protein levels using molecular biology techniques.
• Assessment of Mcl-1 ubiquitination and protein half-life.
• Evaluation of tumor growth inhibition and combination therapy efficacy.

Main Results:

• Decitabine (DAC) treatment activated FBW7 expression and decreased Mcl-1 protein levels in lung cancer cells.
• DAC induced the demethylation and subsequent activation of the FBW7 gene, leading to Mcl-1 degradation.
• DAC suppressed lung cancer growth dose-dependently in vivo.
• Combined DAC and venetoclax treatment showed synergistic anti-cancer effects with minimal normal tissue toxicity.

Conclusions:

• Decitabine (DAC) suppresses lung cancer growth by reactivating the FBW7 tumor suppressor and targeting the FBW7/Mcl-1 pathway.
• The demethylation of FBW7 by DAC is a key mechanism for its anti-cancer activity.
• Combination therapy with DAC and the Bcl2 inhibitor venetoclax represents a promising epigenetic strategy for lung cancer.